C12N 2800/00
Nucleic acids vectors
C12N2800/00 (Nucleic acids vectors) appears on 3,732 US grants and 7,528 published applications in this corpus.
Search patents in C12N- Granted patents
- 3,732
- Published applications
- 7,528
- Assignees
- 2,452
- Inventors
- 12,669
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 1 | 0 |
| 1993 | 6 | 0 |
| 1994 | 8 | 0 |
| 1995 | 5 | 0 |
| 1996 | 18 | 0 |
| 1997 | 48 | 0 |
| 1998 | 67 | 0 |
| 1999 | 45 | 0 |
| 2000 | 67 | 0 |
| 2001 | 49 | 15 |
| 2002 | 57 | 151 |
| 2003 | 58 | 199 |
| 2004 | 42 | 144 |
| 2005 | 44 | 139 |
| 2006 | 48 | 173 |
| 2007 | 57 | 95 |
| 2008 | 42 | 112 |
| 2009 | 56 | 111 |
| 2010 | 57 | 144 |
| 2011 | 56 | 172 |
| 2012 | 72 | 119 |
| 2013 | 77 | 123 |
| 2014 | 98 | 185 |
| 2015 | 93 | 174 |
| 2016 | 116 | 219 |
| 2017 | 125 | 227 |
| 2018 | 139 | 294 |
| 2019 | 173 | 446 |
| 2020 | 207 | 561 |
| 2021 | 247 | 591 |
| 2022 | 307 | 737 |
| 2023 | 287 | 740 |
| 2024 | 320 | 694 |
| 2025 | 391 | 539 |
| 2026 | 243 | 424 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2800/80Vectors containing sites for inducing double-stranded breaksIndexing code1,150
- C12N 2800/10Plasmid dnaIndexing code941
- C12N 2800/30Vector systems comprising sequences for excision in presence of a recombinaseIndexing code711
- C12N 2800/22Vectors comprising a coding region that has been codon optimised for expressionIndexing code450
- C12N 2800/90Vectors containing a transposable elementIndexing code274
- C12N 2800/20Pseudochromosomes, minichrosomosomesIndexing code239
- C12N 2800/40Systems of functionally co-operating vectorsIndexing code144
- C12N 2800/24Vectors characterised by the absence of particular elementIndexing code98
All 12 subgroupsShow fewer
Recent patents
- RNA guide genome editing in citrus using CRISPR-ribonucleoprotein complexes6 Oct 2026US 12,753,413 B2University of Florida Research Foundation, Inc.
- Compositions and methods for the treatment of hemophilia6 Oct 2026US 12,753,418 B2Poseida Therapeutics, Inc.
- Recombinant vector comprising codon-optimized TIF1γ polynucleotide, and use thereof29 Sep 2026US 12,747,274 B2Kim, Cell & Gene Co., Ltd.
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene29 Sep 2026US 12,747,430 B2Precision BioSciences, Inc.
- Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy8 Oct 2026US 2026/0308212 A1Research Institute At Nationwide Children's Hospital
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308231 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308232 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308233 A1Regeneron Pharmaceuticals, Inc.
- Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene8 Oct 2026US 2026/0308549 A1Precision BioSciences, Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998